Waiv Achieves Dual CE Marking Under IVDR, Propelling AI Precision Testing for Breast and Colorectal Cancer for Clinical Routine

Contributed by: Business Wire

Logo

Tags

Biometrics

Biotechnology

Pharmaceutical

Oncology

Health

Artificial Intelligence

Health Technology

Technology

Dual CE Marking Under IVDR

More Like This

Waiv Co-Founders, Meriem Sefta (CEO) and Lionel Guillou (CTO)

Waiv Secures $33 Million to Scale AI Precision Testing

Owkin Announces MSIntuit® CRC v2, a Next-Generation AI Diagnostic Aimed at Transforming the Detection and Treatment of Colorectal Cancer

Owkin and Proscia Expand Access to AI Pre-Screening for Colorectal Cancer Patients

Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing

Diagnostics.ai Launches Industry's First CE-IVDR Certified Transparent AI Platform for Molecular Diagnostics as Regulatory Deadlines take Effect

Owkin enters collaboration agreement with MSD to develop AI-powered diagnostics for cancer

Dxcover Secures CE-IVDR Certification

Owkin Announces International Validation Results of BRCAura: AI-Driven Screening for gBRCA Mutations Directly From Pathology Slides